Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis.

ABSTRACT:

Background

Diabetic ketoacidosis (DKA) is a common, life-threatening complication of type 1 diabetes (T1D) characterized by unregulated ketogenesis caused by relative or absolute insulin deficiency. DKA management requires frequent biochemical monitoring. Plasma ß-hydroxybutyrate (BOHB) has not been included in traditional definitions of DKA resolution.

Objective

The aim of this study was to determine a cut-point level of BOHB to define DKA resolution in patients with T1D treated with intravenous (IV) insulin.

Subjects

We identified patients with T1D receiving IV insulin for DKA treatment at a quaternary children's hospital from January 1, 2017 through December 31, 2020 who had plasma measurements of BOHB after DKA onset and whose DKA resolved by traditional laborator

SUBMITTER: Tremblay ES 

PROVIDER: S-EPMC9772128 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature